SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Incyte (INCY)
An SI Board Since January 1996
Posts SubjectMarks Bans Symbol
3202 131 0 INCY
Emcee:  scaram(o)uche Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
2427BOFA/Merrill INCY future path secured by promising new cancer drug We areDaveyk-12/17/2009
2426so here is Scaltriti et al., n=46...... J Natl Cancer Inst. 2007 Apr 18;99(8):6scaram(o)uche-12/12/2009
2425Data from a Phase I/II Study Presented at the 32nd San Antonio Breast Cancer Symscaram(o)uche-12/12/2009
2424presenting 9:30 a.m. (Pacific), Tuesday 12 January at JP Morgan.scaram(o)uche-12/11/2009
2423Incyte (INCY) Outperform Rating Alert, Watch for 23.3% Technical Uptrend ContinuDaveyk-12/8/2009
2422Market unimpressed, for today at least. <i>8:05AM Incyte announces data ftom pope-12/7/2009
2421Always good to be a bit paranoid when it comes to CEO speak..., and also about bBiotech Jim-11/30/2009
2420Always good to be a bit paranoid when it comes to CEO speak..., and also about bBiotech Jim-11/30/2009
2419>> SB-1518 is a weak signal for Onyx << <i>Phase I Study of tscaram(o)uche-11/30/2009
2418050 has been presented as a follow-on molecule for ages, once daily dosing/oral,scaram(o)uche-11/30/2009
2417What i'm wondering is if there's any real difference between 424 and 050rkrw-11/30/2009
2416I don't understand your question...... they get oncology, whether or not scaram(o)uche-11/30/2009
2415Clin Cancer Res. 2009 Nov 15;15(22):6891-900. Combined inhibition of janus kinascaram(o)uche-11/30/2009
2414AMGN books Enbrel sales in the US and Canada and pays PFE a percentage of gross DewDiligence_on_SI-11/29/2009
2413It's not as if nvs didn't just fork over a large amount of money, huge mrkrw-11/28/2009
2412Thanks. I knew PFE had a large RA/inflamm franchise but did not know they now hquantman-11/28/2009
2411>I have some experience working with GS on large deals, and managing very larformer_pgs-11/28/2009
2410<i>>I believe AMGN [Enbrel] , JNJ [Remicade/Simponi] and Abbott [HumiraDewDiligence_on_SI-11/28/2009
2409If you want to see me or think of me as a pumper, direct or indirect pumper, thequantman211/28/2009
2408>>is this just a roundabout way of pumping<< That seems a little hanigel bates-11/28/2009
2407Can you enumerate the reasons why you think Friedman didn't take the deal thformer_pgs-11/28/2009
2406>> 3.... I have come to the conclusion that Friedman did NOT go with partnnigel bates111/28/2009
2405Belated- I just saw this today. Posting in case some others have not seen this. quantman-11/27/2009
2404SS, thanks for the Bioworld Article. I realize one of the analysts mentioned in quantman-11/27/2009
2403My 2 cents, for what it's worth (probably not much!). You may want to listequantman111/27/2009
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News